Skylands Capital’s Bio-Rad Laboratories Class A BIO Stock Holding History

Skylands Capital’s Portfolio BIO Stock Details BIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.12M	Buy	7,225 +1,575	+28%	+$447K	0.26%	81
2026 Q1	$1.57M	Buy	5,650 +2,050	+57%	+$590K	0.21%	90
2025 Q4	$1.09M	Buy	3,600 +550	+18%	+$172K	0.15%	98
2025 Q3	$855K	Sell	3,050 -950	-24%	-$259K	0.12%	106
2025 Q2	$965K	Buy	4,000 +3,500	+700%	+$827K	0.14%	107
2025 Q1	$122K	Buy	+500	New	+$150K	0.02%	145
2024 Q4	–	Sell	-1,500	Closed	-$502K	–	152
2024 Q3	$502K	Buy	1,500 +100	+7%	+$31.8K	0.07%	121
2024 Q2	$382K	Buy	1,400 +500	+56%	+$145K	0.05%	121
2024 Q1	$311K	Sell	900 -1,250	-58%	-$411K	0.04%	127
2023 Q4	$694K	Buy	+2,150	New	+$674K	0.1%	104

Other funds holding BIO

First Eagle Investment Management New York $60.8B AUM 26.63% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

EARNEST Partners Atlanta, Georgia $27.7B AUM 52.44% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Skylands Capital's BIO Position: Q2 2026 in Review

Skylands Capital increased its Bio-Rad Laboratories Class A (BIO) stake by 28% in Q2 2026, buying an estimated $447K and bringing the position to 7,225 shares worth $2.12M. The position accounts for 0.26% of the portfolio, ranked #81.

Skylands Capital first reported a position in BIO in Q4 2023 and has held it in 10 quarters since. 398 funds tracked by Wall St. Rank hold BIO as of Q2 2026.

Skylands Capital held 7,225 shares of Bio-Rad Laboratories Class A worth $2.12M as of Q2 2026.
Skylands Capital bought 1,575 Bio-Rad Laboratories Class A shares in Q2 2026, an estimated $447K.
Bio-Rad Laboratories Class A made up 0.26% of Skylands Capital's portfolio in Q2 2026, its #81 holding.
Skylands Capital first reported a position in Bio-Rad Laboratories Class A in Q4 2023 and has held it in 10 quarters since.
398 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q2 2026.

Based on Skylands Capital's 13F filing for Q2 2026, filed 24 Jul 2026.